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Addressing the silent pandemic of antimicrobial resistance (AMR) is a focus of the 2021 G7 meeting. A major
driver of AMR and poor clinical outcomes is suboptimal antimicrobial use. Current research in AMR is inequi-
tably focused on new drug development. To achieve antimicrobial security we need to balance AMR research
efforts between development of new agents and strategies to preserve the efficacy and maximise effective-
ness of existing agents.
Combining a review of current evidence and multistage engagement with diverse international stakeholders
(including those in healthcare, public health, research, patient advocacy and policy) we identified research
priorities for optimising antimicrobial use in humans across four broad themes: policy and strategic plan-
ning; medicines management and prescribing systems; technology to optimise prescribing; and context, cul-
ture and behaviours. Sustainable progress depends on: developing economic and contextually appropriatetional Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial
ealth building, Du Cane Road W12 OHS
olmes).
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2 E. Charani et al. / The Lancet Regional Health - Europe 7 (2021) 100161interventions; facilitating better use of data and prescribing systems across healthcare settings; supporting
appropriate and scalable technological innovation. Implementing this strategy for AMR research on the opti-
misation of antimicrobial use in humans could contribute to equitable global health security.
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Antimicrobial resistance (AMR) is one of the leading threats to
human health1,2 requiring multifaceted activity embedded within a
One Health agenda, that takes account of antimicrobial use in human
health, animal health, agriculture, and environment.3,4 In human
health, action is needed in many areas, including underpinning
efforts to prevent and reduce infectious diseases, for example
through improved access to water, sanitation and hygiene, and to
vaccination. Whilst the need for new antimicrobials through research
and development (R&D) is widely acknowledged, 57 it is critical that
AMR research should not be entirely dominated by the development
of new agents, as these alone will not solve this silent pandemic.3,4
More equitable investment in all the aforementioned elements is
needed, as well as in research on optimising antimicrobial use,
including the investigation of how the efficacy of existing and new
antimicrobials can be maximised and how their effectiveness can be
preserved.8 The remarkable success of therapeutic trials and vaccine
development in response to the COVID-19 pandemic shows what is
possible if similar strategies were mobilised for other problems,
including AMR.9 While progress is being made in research initiatives
addressing AMR, important research gaps remain.4,10
Optimisation of antimicrobial use as a means to tackle AMR and
improve the treatment of infections, is a priority of the health agenda
of the June 2021 G7 meeting.11 Antimicrobial use, like much human
behaviour, is complex and dynamic and is influenced by sociocultural
contexts as well as changing population and individual characteris-
tics, such as the increasing prevalence of multimorbidity.12 Interven-
tions developed in one setting may not necessarily work in another
and interventions to optimise antimicrobial use need to extend
beyond a narrow concept of antimicrobial stewardship (AMS)13, and
be based on a comprehensive and inclusive systems approach,
informed by a broad research base.
In this paper we set out a research strategy for optimising antimi-
crobial use in human populations, developed from a review of cur-
rent evidence and a multi-stage process of engagement with diverse
international stakeholders, drawn from academia, clinical medicine,
public health, patient advocacy, and non-governmental organisations
who, together with the authors, include all G7 nations. We have
taken a whole systems approach to the many issues that influence
the use of antimicrobials in human populations,14 arguing for a com-
prehensive research strategy that will allow us to understand the
complexities of technology and innovation adoption and human
behaviour and the many factors that influence them, within health
systems and beyond.1517
2. Search strategy and Selection criteria
In March 2020, an interdisciplinary team of stakeholders was con-
vened, with extensive expertise in medicine (in general infectious
diseases, microbiology, tuberculosis and HIV), surgery, pharmacy,
clinical pharmacology, epidemiology, social science, economics, engi-
neering, public health, patient safety, healthcare management and
policy research, along with patient and public advocates and repre-
sentatives, to identify the current research priorities in optimising
antimicrobial use in human populations. Key stakeholders (32 mem-
bers from 15 countries) were purposively selected based on track-
record, expertise, and representation from all World Health Organi-
zation (WHO) Regions. Between March 2020 and November 2020,via a series of virtual round-table discussions organised and analysed
by the core team, stakeholders contributed to the research process.
Additional individual input was sought from several stakeholders
who were not able to attend the round table discussions. There were
three phases.
Phase 1 Review of existing research and generation of key themes
To provide an overview of current research on optimised antimi-
crobial use in humans a core team (9 of the listed co-authors) gath-
ered evidence through a narrative review of published and selected
grey literature. References were identified through searches on
PubMed with the search terms “antimicrobial resistance”, “antibiotic
resistance”, “national action plans”, “antimicrobial stewardship”, and
“health services” from 1995 until 2020. Articles were also identified
through searches of the authors’ own files. Only papers published in
English were included. The global and national initiatives for funding
and research, capacity building and infrastructure development in
AMR were also reviewed using open resource material. Global poli-
cies, agreements and recommendations such as the Global Antimi-
crobial Resistance Surveillance System and national action plans
(NAPs) for AMR were reviewed.18 The gaps and opportunities for
optimising antimicrobial use in human populations were identified
in the narrative review and discussed in virtual round-table discus-
sions amongst the core team to identify the key emerging themes. A
thematic survey was developed based on these themes to identify
potential barriers and opportunities in advancing research, together
with open questions to capture broader concepts and ideas from local
and national settings. From amongst the stakeholders identified, an
expert panel of seven members was convened. The survey was dis-
seminated via email to the expert panel. The panel members were
requested to identify relevance to context, feasibility, urgency, and
importance of the priority areas for each theme.
Phase 2 Evidence analysis and identification of key priority areas
The feedback from the first-round table, together with feedback
from the expert panel, was used to refine the identified priority areas
and the survey themes and questions. A matrix of emerging research
priority areas and cross-cutting considerations was developed based
on the phase 1 findings. The matrix was then validated via 1) a survey
with open questions disseminated via email to the 32 stakeholders,
and 2) three roundtable, and one-to-one virtual discussions with
selected members of the full stakeholder team.
Phase 3 Validation of the roadmap
The stakeholder feedback elicited in phase two was used by the
core team iteratively to refine the concepts in the roadmap. The evi-
dence-base supporting the roadmap content was regularly updated
by the core team with any emerging evidence (up until 31 January
2021) deemed relevant discussed by the core team before being
included in the final matrix and roadmap. The final roadmap was dis-
cussed and validated with original seven stakeholders in a further
virtual round-table discussion.
3. Four research themes
Our initial review identified four key research themes: policy and
strategic planning, medicines management and prescribing systems,
technology for optimised antimicrobial prescribing, and context, cul-
ture and behaviours. Broadly, there is imbalance in funding with
emphasis on new drug R&D, and very limited funding for the identi-
fied themes (Figure 1). This creates inequalities in impact in terms of
populations who will benefit from the research. In technology and
Figure 1. Current global funding bodies active in antimicrobial resistance research for humans and the broad themes under which funding is available
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than evaluation.
Whilst many of the research opportunities have global eligibility
criteria, they are ultimately funded by high-income countries (HICs).
We need greater accountability and scrutiny of how funding bodies
apportion resources across the AMR agenda, particularly given the
need for capacity building and strengthening.19 It is imperative to
balance research funding and allocate resources for cost-effective ini-
tiatives across the identified themes to achieve equity between R&D
and optimisation in use of existing antimicrobials. The opportunities
and gaps across these themes are discussed as follows.
3.1. Policy and strategic planning
Strategies and tools to support national interventions include the
development and implementation of NAPs for AMR, based on best
available evidence. The 2015 G7 summit in Germany explicitly com-
mitted to this in its Leaders’ Declaration.20 The process by which
NAPs are developed is shaped by political forces as much as the scien-
tific or technical evidence base.21 Given the societal impact of AMR
and the suite of interventions required to tackle the issue at individ-
ual, organisational and societal level, the research informing policy
and management strategies requires a multidisciplinary approach
that includes patient and public representation.
In 2011, the WHO initiated a situational analysis of country prog-
ress in addressing AMR against four objectives: (1) Improvedawareness and understanding of AMR through effective communica-
tion, education, and training; (2) Strengthened knowledge and evi-
dence base through surveillance and research; (3) Reduced incidence
of infection through effective sanitation, hygiene, and infection pre-
vention measures; and (4) Optimised use of antimicrobial medicines
in human and animal health.18 This has been important as an initial
framework but the detail and quality of analyses of national and local
strategies may benefit research that considers AMR as inextricably
linked to other public health and health system level processes and
outcomes.
Following global directives, 117 of 208 countries have govern-
ment-approved AMR NAPs that reflect the WHO Global Action Plan
objectives, but only 26 have identified funding sources.22 The remain-
ing 91 countries are still at the development stage. National situa-
tional analyses are underway in individual countries and as part of
learning networks (e.g., the Global Antibiotic Resistance Develop-
ment Partnership)23 but they employ different frameworks and
approaches that, whilst having local relevance, impede cross-country
or global comparisons or benchmarking. Few, if any, have employed
a strategic management framework15 critical for enabling agile
responses to macro-level environmental influences. Beyond review
and development of plans, there is potential to conduct dedicated
research to understand how disparate health systems within individ-
ual countries are equipped to adopt and implement NAPs. There is
also potential to consider this from a regional perspective. For exam-
ple, countries within the Southern and Eastern African Development
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harmonise strategies. Specific research needs for policy and strategic
planning for AMR are summarised in Box 1.
Box 1 Specific research needs in policy and strategic planning
and the suggested frameworksConsideration of AMR as part of the wider policy agenda
While national efforts are critical, they are shaped by the
wider political and economic global agenda. Considering anti-
microbial resistance (AMR) as a global public health threat
requires commitment at an international level in determining
priorities and formulating policies. This international-level
focus and agenda setting has been initiated through the United
Nations General Assembly and the agreement on Sustainable
Development Goals, however greater advocacy and representa-
tion at the international level is required for there to be effec-
tive and lasting change in policies and strategy. A key area
where international policy can have impact is in legislation for
access to antimicrobials, this includes improving access to qual-
ity-assured antibiotics and restricting unregulated and under
the counter acces. The regulatory aspects of antimicrobials are
important for AMR as they influence access, quality, and equal-
ity in relation to antimicrobials.
Investigation of health systems organisation and
management
Health systems includes health and social care and the role
of non-governmental organisations and civil society. Existing
frameworks have facilitated the rapid appraisal of health inter-
ventinos at a health systems level. The Systematic Rapid Assess-
ment toolkit,90 for example has recently been applied to
examine the extent of integration across the health economy in
a review of the international literature.91 There are also oppor-
tunities for learning from successful health system interventi-
nos, e.g. the largely integrated health and social care responses
to tuberculosis in the Eastern European settings.90
Health system level governance and accountability
The complex nature of system governance is important for
AMR policy and has been analysed at the overall health system
level, and if and how governance at these levels is aligned or
divergent. Health system governance refers to processes, struc-
tures, and organisational traditions that determine how power
is exercised, how stakeholders have their say, how decisions
are taken, and how decision-makers are held to account.92
Three main governance processes — setting priorities, monitor-
ing performance against these priorities, and accountability of
all actors within the system for their expected contribution93 
have been examined, providing case studies of effectiveness in
high-income countries.94,95 A systematic review of the litera-
ture96 provides a synthesis of frameworks for such analyses but
these have yet to be applied to the context of addressing AMR
in low-, and middle-income countries (LMICs).
Role of the private sector
The role of the wider private industry, including private
healthcare providers and insurance companies, and how these
sectors disrupt or align the goals for addressing AMR and anti-
microbial optimisation is not fully explored or understood, par-
ticularly in the LMICs setting. The role of big pharma should not
be ignored. Frameworks exist for assessing how significantly
(positively/negatively) this sector may interact at the global
and national level to initiate and sustain solutions to address
AMR, including classic policy analysis models (e.g. Kingdon’s
model97,98) as well as systematic stakeholder analyses.99
Understanding pluralistic health systemsThe role of pluralistic health systems comprising public, private,
and non-governmental providers as well as the interactions
within them, particularly in LMICs settings, is important in
understanding whether the response to AMR is consistent
across these settings. This is particularly important when there
is open direct access to hospitals and other providers, resulting
in care-seeking behaviours of switching among and between
these domains of care.
3.2. Medicines management and prescribing systems
Medicines management refers to the processes, behaviours and
systems that determine the way that medicines are used in clinical
practice. How antimicrobials are made available in each country
partly depends on how these drugs are classified legally and partly
on the extent to which legislation is monitored and enforced. Non-
prescription access to selected antimicrobials is still prevalent world-
wide in both HICs as well as low-, and middle-income countries
(LMICs), including provision via community pharmacies, online phar-
macies and other retail vendors.24,25 This is partly due to the signifi-
cant lack of prescribers and the pressure of market forces. A balanced
approach that includes some level of control aligned with incentivisa-
tion, training, and monitoring of the non-prescription access path-
ways, is likely to provide a more sustainable mechanism for access to
effective antimicrobials. Mapping of the antimicrobial drug supply
chain for human use revealed gaps in practice at each point of the
R&D and supply chains (Figure 2), including poorly regulated
access,26,27 perverse economic incentives,2830 patient and public
illicit access, access to black market and falsified agents, and public
misbeliefs. There is, however, a need for balance between over-regu-
lation and under-regulation, especially in places where lack of access
to antimicrobials may result in increased morbidity and mortality.
The importance of timely access to antimicrobials is recognised
internationally through their inclusion in country-specific essential
medicines lists (EMLs); however, maintaining an up to date EML
remains a challenge due in part to the number of medicines that
though withdrawn from the market remain on EMLs.31 In 2017 the
WHO introduced the AWaRe (Access, Watch, Reserve) system in the
EML, categorising antibiotics based on their activity against multi-
drug resistant organisms.32 The AWaRe system adds value to point-
prevalence studies on antimicrobial consumption33 and is being used
to measure the change in proportion of AWaRe antimicrobials, with
data reporting rapid increases in consumption in the Watch category,
particularly in LMICs.12 The system has been used to compare pat-
terns of antimicrobial use between countries, advocating for more
use from the access category (up to 60% of total consumption) by
2023 as part of initiatives to help countries reach their health related
sustainable development goals.8,34 A key research gap is understand-
ing how different countries use and adapt the AWaRe system35 and
to what extent it will influence the design, implementation, and sus-
tainability of strategies that balance timely access with reducing
inappropriate use. Furthermore, in many LMICs, protracted shortages
of Access antimicrobials result in use of broader spectrum agents; the
AWaRe system could be enhanced to monitor availability of antimi-
crobials in different regions, countries, and healthcare systems.33,36
3.3. Technology for optimised antimicrobial prescribing
Effective medicines management requires data and technological
advances can support and provide this. The lack of robust data on
how to use antimicrobial agents correctly in different populations
and in the context of multimorbidity, hinders appropriate use and
drives AMR. For example, obesity, an increasing global health con-
cern, is a significant contributor to multimorbidity. Despite this, and
Figure 2. The antimicrobial drug supply chain indicating gaps in current systems and opportunities for research, adapted from the WHO framework for development and steward-
ship to combat antimicrobial resistance (AMR)90
R&D: research and development
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bioavailability and efficacy of different antimicrobials in obese popu-
lations remains inadequately studied,37 resulting in inappropriate
dosing.37,38 Multimorbidity and its associated polypharmacy further
complicate antimicrobial dosing, increasing the risks of therapy fail-
ure and AMR.38 Robust clinical data on the use of different antimicro-
bial agents and antimicrobial dosing in specific populations would
facilitate their optimised use and reduce the risk of emergence of
AMR through inappropriate therapy. Generation of such data
requires strategic epidemiological trials in specific populations (e.g.,
in neonates and paediatrics, in pregnancy, in the obese, in multimor-
bidity). Decision support systems hold considerable potential and
may accelerate antimicrobial optimisation through standardising
mechanisms for large-scale clinical data curation and global data
sharing. Additionally, data linkage across sectors (primary and sec-
ondary) including linkage of clinical indications with antimicrobial
prescriptions is lacking. Enhanced decision support systems can facil-
itate data gathering and analysis at scale from different populations
to support surveillance mechanisms.39
Rapid diagnostic devices, clinical decision support systems, wear-
able devices, and biosensor technologies are some of the existing
technologies in use for infection-related clinical practice that can be
readily applied to optimise antimicrobial use.4042 Artificial intelli-
gence provides another potential for significantly enhancing the abil-
ity to gather robust data for surveillance as well as facilitating
individualised real-time clinical decision-making.43,44 Despite tech-
nological advances, research supporting the integration and sharing
of information generated by individual technological solutions is
lacking. Historically, the development and acceleration of technology
has been concentrated in HICs, despite evidence of rapid adoption
and application of such technologies in LMICs; for example, the use
of drones for blood delivery to remote hospitals, and electronic sur-
veillance of childhood bacterial infections in Bangladesh.45,46Infrastructure and systems limitations can block innovation
uptake. Limitations include the mismatch between available data and
expertise, data being distributed across different entities (without
being linked), and cultural and behavioural barriers to technology
adoption. Technology developed in one setting cannot be assumed to
be directly translatable to other settings. For example, in HICs, spe-
cific strategies focused on reducing antimicrobial prescribing may
have the greatest impact on reducing AMR; however, in LMICs, vac-
cine technology may have a greater impact on reducing lower-respi-
ratory tract infections and thus antimicrobial usage.1,47 Frameworks
for the funding, development, and evaluation of technology must
take such differences into account to ensure that targeted interven-
tions are developed and implemented in an appropriate way.
3.4. Context, culture and behaviours
AMR is a multifaceted issue and its drivers and consequences are
manifested socially.17,48,49 Recognising this, increasingly, social sci-
ence methods have been applied in the study of antimicrobial
use.50,51 A qualitative study in Australia examined how hospital doc-
tors balance competing concerns around antimicrobial use and
AMR.52 With a focus on individual care versus broader public health
considerations, participants did not perceive AMR as central to clini-
cal decision-making and clinical risk was prioritised over population
risk. Under-prescribing was associated with legal and reputational
risk, while overprescribing carried minimal risk to themselves or the
patient. These findings demonstrate the inability of prescribers to
associate their own behaviours with the emergence of AMR, while
simultaneously tending towards over-prescription of antimicrobials
to treat the patient in their care.52
Professional hierarchies as key determinants of antimicrobial
decision-making in hospitals have been described using social sci-
ence research.48,53,54 Prescribing etiquette in hospitals means that
6 E. Charani et al. / The Lancet Regional Health - Europe 7 (2021) 100161hierarchy within and among professions can limit the involvement of
junior members of teams and pharmacists and nurses in key deci-
sion-making, leading to gaps in care and lack of direct responsibility
for actions.48,53,55 Two studies emphasise how interprofessional rela-
tionships between non-infectious disease clinicians and infectious
diseases (ID)/clinical microbiology shape prescribing practices.17,55
Competing hierarchies result in limited consultation with ID/clinical
microbiology, while negotiating clinical ownership and antimicrobial
decisions are influenced by multiple competing authoritative figures.
Antimicrobial decisions are caught between the tensions caused by
evidence-based recommendations by ID/clinical microbiology and
experiential-style learning  a skill passed on from senior doctors to
junior doctors.55 Antimicrobial prescribing decisions in this context
are a balance between the specialists’ advice and the clinicians’
judgement.55
Little is also known regarding the impact and consequences of
social constructs (e.g., gender, ethnicity, race) on AMR or on infection
related behaviours of healthcare workers or the public. This gap in
knowledge is critical as we collectively experience the evolving
COVID-19 pandemic.56 Paradoxically, over 70% of the world’s health-
care providers and carers are female and are thus at greater risk of
acquiring illness themselves while working. Additionally, previous
epidemics have led to disastrous consequences for health and social
well-being of women, e.g. rising maternal mortality during the West
African Ebola outbreak, and increased domestic violence during the
Wuhan lock-down in China in response to COVID-19.57 The majority
of the health workforce driving infection prevention and control
(IPC) in healthcare facilities are female nurses, with the pharmacy
workforce responsible for reviewing antibiotic prescriptions also pre-
dominantly female.58 The differences in gender and class of those
healthcare professionals who study medicine versus other healthcare
professions can influence the power dynamics, with behaviours,
roles, and opportunities based on different levels of power.59
Inequalities harm health and this is equally true for AMR. For
example, in HICs, poverty is associated with drug-resistant infec-
tions.60 In LMICs, a lack of formal education has been linked to resis-
tant Streptococcus pneumoniae and Escherichia coli infection.61 The
intersection of socioeconomic factors and AMR and how it puts indi-
viduals at greater risk of poor outcomes needs to be better under-
stood in order to bring about sustainable change for vulnerable
populations.
4. Cross-cutting systems level considerations
Beyond the four research themes, the engagement with wider
stakeholders and experts identified cross-cutting issues that need
addressing as part of efforts to tackle AMR in human populations:
engagement with the public and capacity building. It is also necessary
to consider the implications of the COVID-19 pandemic that are likely
to shape policies for years to come. These three cross-cutting themes
are discussed below.
4.1. Public engagement
Popular knowledge about antimicrobials is poor and the scale of
the threat of AMR is under appreciated.62,63 National and interna-
tional AMR responses fail to recognise the role of the public and
wider society in efforts to tackle AMR and implement effective IPC.64
Reducing popular demand for antimicrobials must be a key goal of
any AMR strategy; however, research on how best to do this is lim-
ited.2 Existing communication and engagement initiatives often leave
behind the most vulnerable and those at most risk of the negative
consequences of AMR. Within civil society and across systems there
needs to be a greater engagement with and awareness of the threat
of AMR to engender a culture of civil responsibility, activism and sus-
tained accountability. The climate movement is an example ofcollective civil society and public engagement and activism to
address a global threat. There is much to learn from the approaches
applied by climate advocacy campaigns; including the provision of
information that is accessible by citizens and the public, how that
information is framed, and the efforts made to challenge the terms of
political debate. It has been argued that climate campaigns’ success
has been in creating a space for open dialogue and discussion that
emphasises values and focuses on grass-roots engagement.65 Like-
wise, strategies for antimicrobial optimisation need to practice prag-
matic reasoning that considers the interests of all stakeholders.
The Wellcome Trust report ‘Reframing Resistance’ encourages
use of standard language for communication about AMR.66 However,
the language used must be consistent with local understanding of
terminology. Dialogue and active engagement with informal ven-
dors to drive local initiatives may help to address this gap. Research
on public engagement in AMR needs to consider health literacy.67,68
Enhancing health literacy across multiple generations and in differ-
ent contexts, has the potential to facilitate patient and public under-
standing of when to seek healthcare, how to self-care when
appropriate, and how to reduce inappropriate antimicrobial use.
This includes use of context-specific language and communication
styles alongside developing appropriate health literacy assessment
tools.
The role of the public as consumers of healthcare is also impor-
tant.64 Communication and information provision within healthcare
often fails to address the needs of the consumer and may be responsi-
ble for driving many misconceptions and the misuse of
antimicrobials.62,69,70 When technological solutions are co-designed
with end users there is better patient knowledge and understanding
of AMR.71 Early engagement is vital to explore concerns and support
development that will lead to adoption.72 Strategies for the evalua-
tion of the effectiveness of public health initiatives for AMR in rela-
tion to public perceptions, motivations, and behaviours around
antimicrobial use are also needed.73764.2. Capacity building
Significant disparities and inequalities between the capabilities of
HICs and LMICs settings impede global collaboration and research in
AMR. Building capacity in AMR research needs to be much wider and
go beyond primary, secondary, and tertiary care settings across HICs
and LMICs. The strategic capacity to implement the existing NAPs
remains a major concern.77 Gaps in mechanisms for effective surveil-
lance of AMR and infections mean that in many LMICs the true scale
of the problem is not known. The capacity for data gathering, analy-
sis, and sharing needs to be developed to a minimum acceptable
standard across HICs-LMICs to enable the evaluation and benchmark-
ing of population and systems level data on AMR at a global scale.
Accurate, contextually relevant, and timely data are crucial to
enabling not only good science but also the public discourse and
activism needed to tackle AMR.
Current initiatives and practices to address antimicrobial optimi-
sation often leave many in the healthcare workforce behind.7880 The
nursing workforce can make important contributions in IPC, AMS,
and patient and public engagement.81,82 The surgical specialty is
often overlooked in AMS initiatives, and this is despite the high bur-
den of infection in surgical populations, particularly in LMICs.83,84
There must be much greater engagement with all healthcare profes-
sions, across specialties, with sustainable, agile training in AMS and
IPC strategies. The Child Health Research Foundation in Bangladesh
offers a model of capacity building to tackle AMR,85 working with
locally trained community healthcare workers who receive specific
training not only in epidemiological data collection but also in recog-
nition and referral of children with bacterial infectious diseases to
qualified healthcare workers for diagnosis and treatment.46
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Finally, we cannot ignore the consequences of COVID-19. There
are concerns that the pandemic may have an adverse impact on AMR
as many patients with COVID-19 have, often inappropriately, been
treated with antibiotics. However, the situation is complex as whilst
the widespread use of antibiotics in severely ill hospitalised patients
may encourage AMR in acute care, the apparent reduction in infec-
tious diseases seen in the community and reductions in community
use of antibiotics may also have a significant impact.86,87 Further-
more, disruption to research programmes may adversely impact
AMR research. It will be important to harness the opportunities,
including important lessons in reducing transmission of infection.
The experience of the pandemic, and especially the nosocomial
spread of COVID-19, could encourage IPC practices to be revisited.
We need to rethink pandemic preparedness and response beyond
just global health security and look at strengthening multisectoral (e.
g., in One Health) and multilateral approaches (as has been done in
other areas such as HIV), using AMR as the proof of principle.
The barriers that the global health community is facing in tackling
the COVID-19 pandemic can be used as learning. Key areas to focus
research on are the state of public health infrastructure at the local
level (beyond national centres of excellence), public trust in govern-
ment, long-term funding trends for public health (beyond recent or
specialised budgets), and relative political autonomy of public health
systems.
5. Moving forward: a roadmap
In developing this analysis of current evidence and expert consen-
sus on optimising the use of antimicrobials in humans we have iden-
tified global research priorities. However, these now must be
adapted to the situation in each country, as priorities for research are
likely to differ as will the applicability of findings given the differing
contexts. In Figure 3 we set out a possible roadmap, based on the fourFigure 3. The proposed timeline for the identified researcidentified priority themes for research policy and implementation
and with a timeline that we believe will be feasible.
Within countries, the focus should be on: developing economic
and contextually appropriate AMR-specific policy interventions;
facilitating better use of data and prescribing systems across health-
care settings; supporting appropriate and scalable technological
innovation and data linkage and evaluation; and better understand-
ing and accounting for sociocultural and behavioural factors. Follow-
ing this research roadmap, within two years, countries should have
achieved a detailed understanding of the challenges they face and be
able to develop context appropriate policies and interventions appro-
priate to address these challenges. Within five years they should be
implementing them, refining their approach where necessary, and
incorporating emerging developments. By ten years they should be
moving to a sustainable model, incorporating a sustainable system of
research and evaluation.
Action is also needed at regional and global levels, building on
existing structures. From a research policy perspective there are
three broad roles to consider. The first is technical. While some coun-
tries will be able to implement necessary measures using their own
resources, others will need assistance, either because they are small
or because they have limited public health and research capacity. The
public health role is traditionally undertaken by the WHO, and espe-
cially its regional offices. Increasingly, other regional organisations
are entering this space, a process that is accelerating following the
COVID-19 pandemic, exemplified by proposals for a European Health
Union. While much less advanced, other regional groupings, such as
the Association of Southeast Asian Nations (ASEAN) and the African
Union, are developing a health role.88 These regional groupings also
have a role to play in harmonising legislation and policies, recognis-
ing that free trade facilitates movement of not only goods but also
micro-organisms. The development of international norms and
standards has traditionally rested with WHO, this time with its Head-
quarters, the Food and Agriculture Organisation (FAO), working
together in certain areas such as through the Codex Alimentarius inh priorities in optimising antimicrobial use in human
8 E. Charani et al. / The Lancet Regional Health - Europe 7 (2021) 100161relation to foodborne infections. However, given increasing under-
standing of role of agriculture and aquaculture in AMR, there is a case
for stronger and closer alignment between all agencies with a direct
interest in One Health, including WHO, FAO, the World Organisation
for Animal Health (OIE) and the UN Environment Programme.89
The second role is financial. Again, many countries can implement
a roadmap with domestic financial resources, but others cannot. For
LMICs, Multilateral Development Banks and Development Finance
Institutions can play a crucial role if they develop greater expertise in
the investments needed to tackle AMR. Other international financial
institutions, such as the International Monetary Fund, can play a role,
adding progress in reducing the risk of AMR to their monitoring of
environmental, social, and governance indicators that feature in their
discussions with governments. However, many of the measures
needed to combat AMR can be considered as global public goods, in
that investments benefit the entire world.
A third role is foresight. The Intergovernmental Panel on Climate
Change has done much to draw attention to the threats from global
warning, convening leading scientists who can assemble the neces-
sary evidence. As AMR also poses an existential threat to humanity,
there seems a strong case for a similar organisation, such as an Inter-
governmental Panel on Health Threats, that would include AMR in a
broader portfolio of work that would include development and moni-
toring of appropriate indicators of the risks from AMR. We recognise
that the challenges of achieving concerted international action are
considerable. However, the experience in developing a response to
the global financial crisis does suggest that progress is possible when
there is political will and a structure to make things happen. The
Financial Stability Board, established after the 2009 G20 summit,
offers a model for what might be achieved in the health arena.
From a research perspective, population and geographical inequi-
ties among and within HICs and LMICs remain critical barriers to
progress in sustainable research to tackle AMR. To address the gaps
in AMR research in human populations and achieve antimicrobial
security, it is essential to invest in capacity to conduct and apply
research in all HICs and LMICs. Funding and research on AMR remains
heavily skewed towards HICs while current priorities do not capture
the full spectrum of issues relevant to AMR. Most funding is dedi-
cated to surveillance and technology, and while this is necessary 
especially in LMICs where availability of data is limited by underin-
vestment in digital laboratory and prescribing systems  little con-
sideration has been given to building capacity for technology
evaluation, implementation and management science, behavioural
research, and understanding the influence of context on outcomes
and sustainability of interventions. There is also a need for enhanced
mechanisms to enable engagement with policymakers.
Responses to the threat posed by AMR have often been fragmen-
tary, failing to recognise that the solution demands a systems
approach that recognises the complexity unique to AMR which is
influenced not only by the interactions of many different actors, but
also the added complexity of evolution of microorganisms capable of
undergoing rapid unpredictable change. These characteristics call for
a dynamic response based on continuous learning, with close links
between research and policy. We believe that our roadmap creates a
means to achieve this.
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